Biogen Inc. on Wednesday reported positive new data for its multiple sclerosis treatment Tecfidera in clinical and real-world settings. The biotech said the drug significantly reduced the time to a first relapse versus other treatments and affirmed its safety profile in patients who have used it for up to nine years. The company is planning to present the data to the the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London. Biogen shares were not yet active in premarket trade, but are down 3% in the year to date, while the S&P 500 has gained 4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News